Celyad obtains additional US patent for allogeneic cancer treatment based on TCR-deficient CAR-T cells – Business Wire (press release)
|
Celyad obtains additional US patent for allogeneic cancer treatment based on TCR-deficient CAR–T cells
Business Wire (press release) “Allogeneic CAR–T cells are of increasing interest to many Pharma and BioPharma companies involved in cell-based cancer immunotherapies. We are looking to maximize the significant value of our allogeneic CAR-T assets through strategic collaborations … |
